Alexithymia and its relationships with inflammatory response mediated by IL-1 family members.
The major aim of this study is to provide a review of the research studies regarding the clinical link between alexithymia and interleukins (IL). We performed a search for the relevant literature by using search terms as "alexithymia" combined with "interleukin or IL". A total of 9 original research studies were identified and included. Alexithymia was found to be prevalent in inflammatory response and associated with inflammatory cytokines. Our review emphasized for the first time the relationships of alexithymia with inflammatory response mediated by IL-1 family members. Therefore, the screening of alexithymic traits and the administration of appropriate psychological and psychotherapeutical interventions should be integral parts of disease management programs. Supplying such interventions will probably help with prevention of the development of the disease and/or its exacerbation by improving the quality of life of alexithymic individuals.
Department of Clinical Psychology, University of Chieti, Chieti, Italy.
C
C
Conti
Department of Pharmacy, University of Perugia, Perugia, Italy.
Al
Al
Caraffa
Department of Microbiology, University of Thessaloniki, Greece.
S K
SK
Kritas
Clinica dei Pazienti del Territorio, Policlinico Gemelli, Roma, Italy.
G
G
Ronconi
Department of Clinical Psychology, University of Chieti, Chieti, Italy.
M
M
Fulcheri
D000342:Affective Symptoms / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D005786:Gene Expression Regulation; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology*; D000067596:Interleukin-33 / Q000235:genetics / Q000276:immunology; D015850:Interleukin-6 / Q000235:genetics / Q000276:immunology; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D020928:Mitogen-Activated Protein Kinases / Q000235:genetics / Q000276:immunology; D020033:Protein Isoforms / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D011619:Psychotropic Drugs / Q000627:therapeutic use; D011788:Quality of Life; D015398:Signal Transduction
D000893:Anti-Inflammatory Agents; C506536:IL33 protein, human; C508600:IL6 protein, human; D007375:Interleukin-1; D000067596:Interleukin-33; D015850:Interleukin-6; D020033:Protein Isoforms; D011619:Psychotropic Drugs; D020928:Mitogen-Activated Protein Kinases